Michael J. Birrer

Top papers

• Integrated genomic analyses of ovarian carcinoma

  Debra Bell, Andrew Berchuck, Andrew Berchuck, et al.·2011·Nature
  ↗ 8,099OA
• Pan-cancer analysis of whole genomes

  Lauri A. Aaltonen, Federico Abascal, Adam Abeshouse, et al.·2020·Nature
  ↗ 3,243OA
• Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

  Robert A. Burger, Mark F. Brady, Michael A. Bookman, et al.·2011·New England Journal of Medicine
  ↗ 2,371OA
• Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis

  Marcel Verheij, Ron Bose, Xin Lin, et al.·1996·Nature
  ↗ 1,794
• Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

  David D.L. Bowtell, Steffen Böhm, Ahmed A. Ahmed, et al.·2015·Nature reviews. Cancer
  ↗ 1,412OA
• p53: A Frequent Target for Genetic Abnormalities in Lung Cancer

  Takashi Takahashi, Marion M. Nau, Itsuo Chiba, et al.·1989·Science
  ↗ 1,230
• <i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group

  Kathryn Alsop, Sián Fereday, Cliff Meldrum, et al.·2012·Journal of Clinical Oncology
  ↗ 1,168OA
• Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

  Ursula A. Matulonis, Ronnie Shapira‐Frommer, Alessandro D. Santin, et al.·2019·Annals of Oncology
  ↗ 817OA
• Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73

  Tod Smeal, Bernard Binétruy, Daniel A. Mercola, et al.·1991·Nature
  ↗ 800
• Dicer, Drosha, and Outcomes in Patients with Ovarian Cancer

  William M. Merritt, Yvonne G. Lin, Liz Y. Han, et al.·2008·New England Journal of Medicine
  ↗ 718OA
• Proteogenomic and metabolomic characterization of human glioblastoma

  Liang-Bo Wang, Alla Y. Karpova, Marina A. Gritsenko, et al.·2021·Cancer Cell
  ↗ 678OA
• Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

  Krishnansu S. Tewari, Michael W. Sill, Richard T. Penson, et al.·2017·The Lancet
  ↗ 669OA